FibroBiologics, Inc. Common Stock (FBLG) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-21.2%

$0.73

vs $0.92 price

Levered DCF

$1.11

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-16.92

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
P/E	-0.54×	-5.88×	-49.32×	-181.88×	-597.54×	-808.33×
P/B	1.63×	24.04×	754.6×	-236.51×	-732.63×	0×
P/S	0×	0×	0×	0×	0×	0×
EV / EBITDA	-0.43×	-5.9×	-59×	-217.32×	-599.48×	0×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	3.61×	1.12×	1×	0.37×	0.27×	0×
Debt / equity	0.39×	3.86×	1.39×	-1.88×	-1.01×	0×
Interest coverage	-81.61×	-686.85×	-60.47×	-6.83×	-394.5×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Return on equity	-302.9%	-408.1%	-1315.6%	128.2%	122.6%	0.0%
Return on invested capital	-194.4%	-103.4%	-296.3%	-126.6%	-15780.0%	0.0%
Return on assets	-193.8%	-67.9%	-139.5%	-106.2%	-338.0%	0.0%
Free cash flow yield	-165.8%	-18.4%	-0.7%	-0.4%	-0.1%	-0.1%
Earnings yield	-185.6%	-17.0%	-1.7%	-0.5%	-0.2%	-0.1%
Enterprise value	$7.6M	$62.3M	$938.1M	$950.3M	$946M	$945.5M
Net debt / EBITDA	0.14×	0.32×	0.47×	-1.2×	-0.57×	0×
Cash conversion cycle (days)	-415	0	0	0	0	0